preloader

1668(E)

(Published in Part II, Section 3, Sub-section (ii) of

the Gazette of India, Extraordinary, dated the 27th September, 2007)

Government of India

Ministry of Chemicals and Fertilizers

National Pharmaceutical Pricing Authority

New Delhi, the 27th September, 2007

ORDER

 

S.O. 1668(E)- In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Price Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority hereby fixes/revises the prices as specified in column (5) of the Table hereto annexed as the retail price/revised retail price, exclusive of excise duty, sales taxes/VAT and local taxes, if any, and in column (6) equivalent MRP inclusive of excise duty, education cess, sales tax / VAT in relation to each of the formulations specified in the corresponding entry in column (2) of the said Table with pack size specified in the corresponding entries in column (3) thereof; manufactured by M/s. Novo-Nordisk (India) Pvt. Ltd.

TABLE

 

Sl. No. Name of the Formulation Pack Size Existing         Retail Price          (Rs.)   Retail Price      without  Excise Duty   Sales Tax /VAT and Local Tax, if any     (Rs.) Equivalent MRP*(inclusive of all taxes)(Rs.)     (Rs.)  
(1) (2) (3) (4) (5) (6)
1 Insulatard HM Penfill100IU Highly Purified Isophane      Insulin Suspension (Monocomponent Human)         Insulatard HM Penfill-100IU/ml 5x3m Cartridgel 1044.70 999.22 1039.19
2 Mixtard 30HM Penfill 100IU Mixture of Highly Purified   Neutral Insulin Solutions and Isophane Suspension   (Monocomponent Human)    Human Mixtard 30HM Penfill-100IU/ml 5x3ml      Cartridge 1044.70 999.22 1039.19
3 Mixtard 50HM Penfill100IU   Mixture of Highly Purified            Neutral Insulin Solutions and Isophane Suspension      (Monocomponent Human)  Mixtard 50HM Penfill-100IU/ml 5x3ml      Cartridge 1044.70 999.22 1039.19
4 Actrapid HM Penfill 100IU       Highly Purified Neutral Insulin      (Monocomponent Human)    Actrapid HM Penfill-100IU/ml 5x3ml      Cartridge 1044.70 999.22 1039.19
5 Mixtard 30 Novolet  Mixture of Biosynthetic Neutral   Human Insulin Solution (30%) and      Isophane Insulin Suspension (70%)-100IU/ml       in 3ml precision delivery device 5x3ml      Cartridge 1305.90 1367.97 1422.69
6 ActrapidNovolet       Biosynthetic Neutral   Human Insulin     100IU/ml in 3ml precision delivery device 5x3ml      Cartridge 1305.90 1367.97 1422.69
7 Mixtard 50Novolet  Mixture of Biosynthetic Neutral     Human Insulin Solution (50%) and  Isophane Insulin Suspension (50%)-100IU/ml in 3ml precision delivery device 5x3ml      Cartridge 1305.90 1367.97 1422.69
8 InsulatardNovolet  Biosynthetic Human Isophane         Insulin Suspension 100IU/ml in 3ml precision delivery device 5x3ml      Cartridge 1305.90 1367.97 1422.69

 

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a)        The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b)        The companies / manufacturers may added taxes only if they have paid actually to the Government on the price mentioned in the column (5).  If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.

(c)        For different packing material used or any special feature claimed, companies are required to approach NPPA for approval/fixation of specific prices.

(d)        These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.

(e)        The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

PN/96/2007/F

F. No. 8(6)/2007/D.P./NPPA-Div.-II

                                                                                                                       (A. K. PAL)

                                                                                                                     Deputy Director

Last Page Updated: 01-06-2019